Skip to main content
Equibles
ANIK logo

ANIK · Anika Therapeutics, Inc. · Analyst Estimates

Track ANIK — free

Use ANIK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANIK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.86 -0.13 (-0.62%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 53% of revenue

One customer — 53% of revenue (the three-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2026)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the six-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”

One customer — 50% of revenue (the three-months ended June 30, 2025)

“Revenue from the Company's sole significant customer, Johnson & Johnson MedTech ("J&J MedTech"), part of the Johnson & Johnson Medical Companies, as a percentage of the Company's total revenue was 53% and 50% for the three-months ended June 30, 2026, and 2025, respectively, and 50% for the six-months ended June 30, 2026, and 2025.”
View the 10-Q filed Jul 29, 2026
Market Cap
$279.70M
Shares
13.38M

Analyst Estimates

Compare analyst forecasts for Anika Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Source collection is delayed; the retained verified snapshot may not include newer publications.

Consensus not yet available

Source collection is delayed; the retained verified snapshot may not include newer publications.

Key facts CIK 898437 CUSIP 035255108 13F (30d) 70 filings 70 filers Visit website Investor relations